🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareGLP-1 and inflammatory markers — need advice

GLP-1 and inflammatory markers — need advice

labquiet_amy Sat, Jul 12, 2025 at 7:30 AM 42 replies 1,888 viewsPage 1 of 9
This thread is more than 11 months old. Information may be outdated. Consider searching for more recent discussions.
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Jul 12, 2025 at 7:30 AM#1

I keep finding that the number in the press summary and the number in the paper are not the same number, and the difference is always in the same direction.

A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.

The question I want answered is how to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases.

Numbers rather than impressions, if you have them.

16 11TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 13 others
Reply Quote Save Share Report
LarryQC_SD
Senior Member
2,123
9,876
Jan 2024
San Diego, CA
Jul 12, 2025 at 7:52 AM#2

Answering the narrow version, because the broad one does not have a single answer. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.

Last edited: Jul 12, 2025 at 8:52 AM
15 10paul_denver, TinaHashiRN, robert_kc and 12 others
Reply Quote Save Share Report
Dr.DermMIA
Member
456
2,123
May 2024
Miami, FL
Jul 12, 2025 at 8:14 AM#3
LarryQC_SD said:
Relative and absolute effects need reading together.

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 25,000 GLP-1 users vs matched controls showed reduced stroke risk (HR 0.82) over 5 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

References:
[1] Registry-based cohort study, pre-print 2024.
14 9A1cHero_PHX, Dr.RenalNash, LipidDoc_ATL and 11 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
alex_tucson
Member
567
2,345
May 2024
Tucson, AZ
Jul 12, 2025 at 8:36 AM#4
labquiet_amy said:
I keep finding that the number in the press summary and the number in the paper are not the same number, and the difference is always in the same…

This matches mine closely enough to be worth saying so. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

13 8ricardo_MIA, BrianDallas92, labquiet_amy and 10 others
Reply Quote Save Share Report
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Jul 12, 2025 at 10:32 AM#5

Adding the clinical framing, because it changes how the question reads.

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

12 7LabKate, kate.chem, DataDave and 9 others
Reply Quote Save Share Report
1239

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register